Editas Medicine Inc (EDIT)
2.44
+0.07
(+2.95%)
USD |
NASDAQ |
Nov 22, 16:00
2.435
0.00 (0.00%)
After-Hours: 20:00
Editas Medicine Cash from Operations (Quarterly): -52.59M for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -52.59M |
| June 30, 2024 | -57.06M |
| March 31, 2024 | -49.87M |
| December 31, 2023 | -22.24M |
| September 30, 2023 | -35.46M |
| June 30, 2023 | -38.71M |
| March 31, 2023 | -35.77M |
| December 31, 2022 | -42.27M |
| September 30, 2022 | -48.00M |
| June 30, 2022 | -37.84M |
| March 31, 2022 | -49.23M |
| December 31, 2021 | -34.58M |
| September 30, 2021 | -40.78M |
| June 30, 2021 | -38.96M |
| March 31, 2021 | -49.48M |
| December 31, 2020 | -40.10M |
| September 30, 2020 | -54.80M |
| June 30, 2020 | -30.86M |
| March 31, 2020 | -54.09M |
| December 31, 2019 | 41.02M |
| Date | Value |
|---|---|
| September 30, 2019 | -26.88M |
| June 30, 2019 | -25.81M |
| March 31, 2019 | -29.00M |
| December 31, 2018 | 1.327M |
| September 30, 2018 | -7.841M |
| June 30, 2018 | -16.73M |
| March 31, 2018 | -22.46M |
| December 31, 2017 | -25.07M |
| September 30, 2017 | -27.98M |
| June 30, 2017 | -26.16M |
| March 31, 2017 | 69.79M |
| December 31, 2016 | -13.68M |
| September 30, 2016 | -17.04M |
| June 30, 2016 | -9.899M |
| March 31, 2016 | -9.629M |
| December 31, 2015 | -8.008M |
| September 30, 2015 | -11.94M |
| June 30, 2015 | 20.45M |
| March 31, 2015 | -5.943M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-57.06M
Minimum
Jun 2024
41.02M
Maximum
Dec 2019
-38.58M
Average
-40.44M
Median
Cash from Operations (Quarterly) Benchmarks
| Ionis Pharmaceuticals Inc | -114.99M |
| EyePoint Pharmaceuticals Inc | -39.03M |
| Cassava Sciences Inc | -18.30M |
| Adverum Biotechnologies Inc | -21.12M |
| Regenxbio Inc | -40.55M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 83.98M |
| Free Cash Flow | -191.36M |
| Free Cash Flow Per Share (Quarterly) | -0.673 |
| Free Cash Flow to Equity (Quarterly) | -55.51M |
| Free Cash Flow Yield | -95.49% |